VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Sony Group Corporation vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Sony Group Corporation
6758 · Tokyo Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Sony Group Corporation's moat claims, evidence, and risks.
View 6758 analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Sony Group Corporation leads (75 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: Sony Group Corporation has 5 segments (37.8% in Game & Network Services); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Moat breadth: Sony Group Corporation has 8 moat types across 4 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
Sony Group Corporation
Game & Network Services
Console gaming platforms and associated network services
Global
Consumers (players) and game developers/publishers
Platform owner + publisher + hardware OEM
37.8%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
Sony Group Corporation strengths
Gilead Sciences, Inc. strengths
Segment mix
Sony Group Corporation segments
Full profile >Game & Network Services
Oligopoly
Music
Oligopoly
Pictures
Oligopoly
Entertainment, Technology & Services
Competitive
Imaging & Sensing Solutions
Quasi-Monopoly
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.